Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Arellano, Martha; J. Thirman, Michael; F. DiPersio, John; Heiblig, Maël; M. Stein, Eytan; C. Schuh, Andre; Žučenka, Andrius; de Botton, Stéphane; Grove, Carolyn; N. Mannis, Gabriel; Papayannidis, Cristina; E. Perl, Alexander; C. Issa, Ghayas; Aldoss, Ibrahim; Bajel, Ashish; S. Dickens, David; W.M. Kühn, Michael; Mantzaris, Ioannis; Raffoux, Emmanuel; Traer, Elie; Amitai, Irina; Döhner, Hartmut; Greco, Corinna; Kovacsovics, Tibor; M. McMahon, Christine; Montesinos, Pau; Pigneux, Arnaud; J. Shami, Paul; M. Stone, Richard; Wolach, Ofir; G. Harpel, John; Chudnovsky, Yakov; Li, Yu; G. Bagley, Rebecca; R. Smith, Angela; S. Blachly, James

doi:10.1182/blood.2025028357

Public

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study

Published in Blood • May 7, 2025

Authors:

Martha Arellano

Michael J. Thirman

John F. DiPersio

Abstract

ABSTRACT: The prognosis for relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a potent, selective menin inhibitor, was recently approved for the treatment of R/R acute leukemia with a KMT2A transl...

Subject

Medicine

Internal medicine

Discontinuation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!